Diabetes News

Endocrinology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Brue T et al. – Analysis of the baseline features of these patients treated with pegvisomant and reported in the ACROSTUDY database underscores the severity of the disease in this subset of patients with acromegaly previously unresponsive to several medical, surgical or radiation treatment approaches.

Related Articles

The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09    Relevance Score: 88%

Associations between Body Composition, Circulating Interleukin-1 Receptor Antagonist, Osteocalcin, and Insulin Metabolism in Active Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/20/09    Relevance Score: 87%

The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly
Journal of Clinical Endocrinology and Metabolism, 11/12/09    Relevance Score: 87%

Discordant Nadir GH After Oral Glucose and IGF-I Levels on Treated Acromegaly: Refining the Biochemical Markers of Mild Disease Activity
Hormone and Metabolic Research, 10/06/09    Relevance Score: 87%

Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients
Clinical Endocrinology, 10/15/09    Relevance Score: 85%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address